Filing Flows

Filing Flows › Theriva Biologics (TOVX) › Who owns the stock

Who owns Theriva Biologics (TOVX) stock

28 funds reported Theriva Biologics (TOVX) shares in their latest 13F filings, worth $557K in all. The largest holder is Vanguard Capital Management LLC ($122K). Last quarter 11 funds added to their stakes and 8 cut them.

Largest holders of TOVX (13F)Largest holders of TOVX (13F)Vanguard Capital Management LLC$122KJane Street Group, LLC$83KGeode Capital Management, LLC$74KVanguard Fiduciary Trust$60KVanguard Group$54KIkarian Capital, LLC$28KVirtu Financial LLC$22KNorthern Trust$21KRenaissance Technologies LLC$16KUBS Group AG$15K

Largest holders (13F)

FundSharesValueChangeQuarter
Vanguard Capital Management LLC486,179$122Kincrease2026-06-30
Jane Street Group, LLC331,922$83Kincrease2026-06-30
Geode Capital Management, LLC294,021$74Kdecrease2026-06-30
Vanguard Fiduciary Trust241,780$60Kunchanged2026-06-30
Vanguard Group255,727$54Kincrease2025-12-31
Ikarian Capital, LLC112,076$28Kunchanged2026-06-30
Virtu Financial LLC87,138$22Kdecrease2026-06-30
Northern Trust82,700$21Knew2026-06-30
Renaissance Technologies LLC63,710$16Knew2026-06-30
UBS Group AG61,053$15Kdecrease2026-06-30
XTX Topco53,868$13Kdecrease2026-06-30
Ground Swell Capital, LLC35,292$9Knew2026-06-30
StoneX Group32,106$7Knew2026-09-30
Boothbay Fund Management, LLC27,646$7Kunchanged2026-06-30
Susquehanna International Group, LLP24,064$6Knew2026-06-30

Theriva Biologics' latest quarter

Theriva Biologics, Q1 2026: revenue $300K, operating margin -709.0%, net loss $2.0M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most TOVX stock?

By the latest 13F filings: Vanguard Capital Management LLC ($122K); Jane Street Group, LLC ($83K); Geode Capital Management, LLC ($74K); Vanguard Fiduciary Trust ($60K); Vanguard Group ($54K).

What is the short interest in TOVX?

1,846,818 shares were sold short at the 2026-10-15 settlement, 7.84% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.